1. Home
  2. LNG vs XGN Comparison

LNG vs XGN Comparison

Compare LNG & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cheniere Energy Inc.

LNG

Cheniere Energy Inc.

HOLD

Current Price

$197.21

Market Cap

46.4B

Sector

Utilities

ML Signal

HOLD

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$5.98

Market Cap

138.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNG
XGN
Founded
1983
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.4B
138.0M
IPO Year
1997
2019

Fundamental Metrics

Financial Performance
Metric
LNG
XGN
Price
$197.21
$5.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
6
Target Price
$265.83
$13.67
AVG Volume (30 Days)
2.0M
321.5K
Earning Date
02-19-2026
11-04-2025
Dividend Yield
1.13%
N/A
EPS Growth
14.15
N/A
EPS
17.92
N/A
Revenue
$18,937,000,000.00
$63,599,000.00
Revenue This Year
$30.79
$21.76
Revenue Next Year
$13.52
$15.63
P/E Ratio
$10.94
N/A
Revenue Growth
21.55
14.08
52 Week Low
$186.20
$2.67
52 Week High
$257.65
$12.23

Technical Indicators

Market Signals
Indicator
LNG
XGN
Relative Strength Index (RSI) 50.33 32.38
Support Level $191.64 $5.74
Resistance Level $199.23 $6.21
Average True Range (ATR) 3.77 0.31
MACD 1.47 0.08
Stochastic Oscillator 71.88 33.96

Price Performance

Historical Comparison
LNG
XGN

About LNG Cheniere Energy Inc.

Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Share on Social Networks: